Kajian Efek Samping Pada Pasien Kanker Payudara Dengan Regimen Paclitaxel-Epirubicin-Fluorouracil di RSUD Kabupaten Temanggung

Satya Prima Kustanto; Retno Murwanti; Agung Endro Nugroho

doi:10.22146/farmaseutik.v19i4.89064

Kajian Efek Samping Pada Pasien Kanker Payudara Dengan Regimen Paclitaxel-Epirubicin-Fluorouracil di RSUD Kabupaten Temanggung

https://doi.org/10.22146/farmaseutik.v19i4.89064

Satya Prima Kustanto⁽¹⁾, Retno Murwanti^(2*), Agung Endro Nugroho⁽³⁾

(1) Program Pascasarjana Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(3) Departemen Farmakologi dan Farmasi Klinik, Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract

Kanker payudara merupakan salah satu kanker yang banyak terjadi dan sering menyebabkan kematian tertingi pada wanita. Kemoterapi merupakan salah satu modalitas terapi yang direkomendasikan pada pasien kanker payudara yang dinilai efektif namun menghasilkan efek samping dan berefek toksik pada sel normal. Penelitian ini bertujuan untuk mengetahui gambaran kejadian efek samping obat hematologi dan non hematologi yang menjalani kemoterapi. Penelitian ini dilakukan di RSUD Kabupaten Temanggung pada bulan Juni-Juli 2023 dengan rancangan cohort retrospective study melalui data sekunder dari rekam medis dan data laboratorium. Dari 47 pasien yang menjalani kemoterapi mingguan dengan regimen kombinasi paclitaxel 60mg/m², epirubicin 50mg/m² dan fluorouracil 300mg/m² diamati, kejadian efek samping hematologi yang paling banyak dialami oleh pasien adalah anemia sebanyak 70.2%, leukopenia 55.3%, neutropenia 27.7% dan peningkatan SGOT dan SGPT 12.8%. Efek samping non hematologi yang paling banyak terjadi adalah rambut rontok 91.5%, mual 82.9%, stomatitis 61.7%, kuku menghitam 48.9%, reaksi hipersensitivitas 46.8%, neuropati perifer 31.9%, sembelit 27.7% dan diare 10.6%.

Keywords

Efek samping; Kanker payudara; Kemoterapi

Full Text:

PDF

References

Anan, K., Tanaka, M., Yoshinaga, Y., Maeda, S., Yamaguchi, Y., Hayashi, M., Tanaka, M., Kamata, Y., Mashino, K., Yamamoto, Y., Nishimura, J., Matsuo, S., Toyoshima, S., Tamura, K., Mitsuyama, S., & Kuyshu Brest Cancer Study Group. (2015). [Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer—A multicenter study]. Gan to Kagaku Ryoho. Cancer & Chemotherapy, 42(1), 45–50.

Ashariati, A. (2019). Manajemen Kanker Payudara Komprehensif. Airlangga University Press.

Basuki, A. R., Perwitasari, D. A., & Hardiyanto, H. (2020). Adverse Drud Reactions (ADRS) Antikanker Pada Pasien Ca Mammae Yang Menjalani Kemoterapi Di RSUD Kota Yogyakarta. Jurnal Health Sains: p–ISSN : 2723-4339 e-ISSN : 2548-1398, Vol. 1, No. 6.

Chan, J., Adderley, H., Alameddine, M., Armstrong, A., Arundell, D., Fox, R., Harries, M., Lim, J., Salih, Z., Tetlow, C., Wong, H., & Thorp, N. (2021). Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres. European Journal of Cancer Care, 30(3).

Darmawan, E., Reina, M., & Budi, R. (2019). Gambaran Hubungan Regimen Dosis dan Efek Samping Kemoterapi pada Pasien Kanker di RSUD Prof. Dr. Margono Soekarjo Purwokerto Periode Bulan Januari-Februari Tahun 2019. Majalah Farmasetik, 15.

DiPiro, J. T. (Ed.). (2020). Pharmacotherapy: A pathophysiologic approach (Eleventh edition). McGraw Hill Medical.

Dorr, V. J. (1998). A practitioner’s guide to cancer-related alopecia. Seminars in Oncology, 25(5), 562–570.

Kandoth, F., K, S., & M, D. (2017). Adverse Drug Reactions in Non-Metastatic Breast Cancer Patients Treated with Anthracycline-Taxane and +/- Carboplatin and/or +/- Trastuzumab-based Regimens: A Prospective Cohort Study from Tertiary Care Teaching Hospital, South India. iMedPub Journals, 2. https://www.imedpub.com/articles/adverse-drug-reactions-in-nonmetastaticbreast-cancer-patients-treated-withanthracyclinetaxane-and--carboplatinandor--trastuzumabba.pdf

Koczwara, B., Meng, R., Battersby, M., Mangoni, A. A., Spence, D., & Lawn, S. (2023). Comorbidities and their management in women with breast cancer—An Australian survey of breast cancer survivors. Supportive Care in Cancer, 31(4), 212.

Kodati, D., Tirumala, S., Kantheti, R. K., & Thumma, J. P. R. (2019). A Retrospective Study on the Adverse Effects of Chemotherapy in Breast Cancer-A Multicenter Study. Indian Journal of Pharmacy Practice, 12(2), 111–116.

Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., Kelley, M. R., Lavino, A., Lustberg, M. B., Paice, J. A., Schneider, B. P., Lavoie Smith, E. M., Smith, M. L., Smith, T. J., Wagner-Johnston, N., & Hershman, D. L. (2020). Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 38(28), 3325–3348.

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers, 13(17), 4287.

Nechuta, S., Lu, W., Zheng, Y., Cai, H., Bao, P.-P., Gu, K., Zheng, W., & Shu, X. O. (2013). Comorbidities and breast cancer survival: A report from the Shanghai Breast Cancer Survival Study. Breast Cancer Research and Treatment, 139(1), 227–235.

O’Reilly, M., Mellotte, G., Ryan, B., & O’Connor, A. (2020). Gastrointestinal side effects of cancer treatments. Therapeutic Advances in Chronic Disease, 11, 204062232097035.

Palappallil, D., Ramnath, S., & Gangadhar, R. (2017). Adverse drug reactions: Two years’ experience from a tertiary teaching hospital in Kerala. National Journal of Physiology, Pharmacy and Pharmacology, 7(4), 1.

Paus, R., Haslam, I. S., Sharov, A. A., & Botchkarev, V. A. (2013). Pathobiology of chemotherapy-induced hair loss. The Lancet Oncology, 14(2), e50–e59.

Razis, E. D., & Fountzilas, G. (2001). Paclitaxel: Epirubicin in metastatic breast cancer – a review. Annals of Oncology, 12(5), 593–598.

Remesh, A. (2012). Toxicities of anticancer drugs and its management. International Journal of Basic & Clinical Pharmacology, 1(1), 2.

Senkus-Konefka, E., Cardoso, F., Douillard, J.-Y., Bramley, C., Longo, F., & jezdic, S. (2018). Breast Cancer An ESMO guide for patients. ESMO. https://www.esmo.org/ content/download/6593/114959/1/EN-Breast-Cancer-Guide-for-Patients.pdf

Sibaud, V., Lebœuf, N. R., Roche, H., Belum, V. R., Gladieff, L., Deslandres, M., Montastruc, M., Eche, A., Vigarios, E., Dalenc, F., & Lacouture, M. E. (2016). Dermatological adverse events with taxane chemotherapy. European Journal of Dermatology, 26(5), 427–443.

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.

Zhu, W., & Xu, B. (2015). Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. PLoS ONE, 10(8), e0136268.

DOI: https://doi.org/10.22146/farmaseutik.v19i4.89064